CRISPR Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 407
- Market Cap
- -
- Website
- http://www.crisprtx.com
- Introduction
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Global Genome Editing Market to Grow at 13.9% CAGR, Reaching USD 17.5 Billion by 2031
The global genome editing market, valued at USD 5.5 billion in 2022, is projected to grow at a CAGR of 13.9% to USD 17.5 billion by 2031, driven by advancements in CRISPR and other gene-editing technologies, increasing applications in therapeutics and agriculture, and rising investments in genetic research and development.
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood sees transformative potential in biologics, driven by AI, genetic sequencing, and gene editing, exemplified by breakthroughs in sickle cell disease treatment and AI-accelerated drug development, despite market volatility.
Increased Investment in Biotechnology: A Key Driver Transforming the Cas Nuclease Market 2024
The Cas nuclease market is forecasted to grow from $2.75 billion in 2023 to $6.56 billion by 2028 at a CAGR of 19.0%, driven by advancements in genome editing, increased biotechnology funding, and demand for personalized medicine.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024
The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast
The T-Cell Lymphoma Pipeline Insight Analysis Report highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing therapies such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, accelerates novel treatment development, aiming to improve patient outcomes in this aggressive cancer.
Investing in Genomics: A Beginner's Guide
Genomics, the study of an organism's complete DNA, integrates with proteomics and metabolomics to revolutionize disease detection and treatment. Advances in DNA sequencing have reduced costs and time, making genomics integral to healthcare. The sector is expected to grow significantly, driven by government grants and increasing cancer incidence. Functional genomics, particularly CRISPR/Cas9 research, leads current advancements. North America dominates the market, but Asia-Pacific is expected to close the gap. Investors can gain exposure through ETFs, individual stocks, or private equity, though challenges include workforce shortages and data integration.
Hemoglobinopathy Treatment Advancements: Global Market Forecast 2024
The hemoglobinopathies treatment market is projected to grow from $8.2 billion in 2023 to $13.2 billion by 2028, driven by genetic inheritance, advancements in cell-based gene therapies, and personalized medicine. Key players include Pfizer, Sanofi, and Vertex Pharmaceuticals.
Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Fulcrum Therapeutics' stock dropped >60% after its Phase 3 REACH trial for losmapimod, a potential FSHD treatment, missed its primary endpoint, leading to the suspension of the program.
Sickle Cell Disease Market Size, Growth, Trends, Report 2032
The Sickle Cell Disease Market, valued at 3.54 USD Billion in 2022, is projected to grow to 12.56 USD Billion by 2032, with a CAGR of 13.5%. Growth is driven by rising prevalence, advancements in gene therapy, and increased awareness. Key trends include precision medicine, digital health technologies, and patient-centered care, with significant opportunities in gene editing and targeted therapies.
© Copyright 2025. All Rights Reserved by MedPath